Fondaparinux drug interactions: Difference between revisions

Jump to navigation Jump to search
Abdurahman Khalil (talk | contribs)
No edit summary
WikiBot (talk | contribs)
m Protected "Fondaparinux drug interactions": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))
 
(5 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Fondaparinux#Drug Interactions]]
{{Fondaparinux}}
{{CMG}}; {{AE}} {{AZ}}


==Drug Interactions==
[[Category: Cardiovascular Drugs]]
In clinical studies performed with ARIXTRA:
[[Category: Drug]]
:*The concomitant use of oral anticoagulants (warfarin), platelet inhibitors ([[acetylsalicylic acid]]), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium. In addition, ARIXTRA neither influenced the pharmacodynamics of [[warfarin]], [[acetylsalicylic acid]], [[piroxicam]], and [[digoxin]], nor the pharmacokinetics of [[digoxin ]]at steady state.
[[Category: Anticoagulants]]
:*Agents that may enhance the risk of hemorrhage '''should be discontinued''' prior to initiation of therapy with ARIXTRA unless these agents are essential. If co-administration is necessary, '''monitor patients closely for hemorrhage'''. [See[[Fondaparinux warnings and precautions| Warnings and Precautions (5.1)]].]
 
In an in vitro study in human liver microsomes:
:*Inhibition of [[CYP2A6 ]]hydroxylation of [[coumarin ]]by fondaparinux (200 micromolar i.e., 350 mg/L) was 17 to 28%. Inhibition of the other isozymes evaluated (CYPs 1A2, 2C9, 2C19, 2D6, 3A4, and 3E1) was 0 to 16%.
:*Since fondaparinux '''does not markedly inhibit [[CYP450s|CYP450]]''' (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro, fondaparinux sodium is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes.
 
'''Protein-Binding Displacement'''
 
Since fondaparinux sodium does not bind significantly to plasma proteins other than ATIII, '''no drug interactions by protein-binding displacement''' are expected.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher =  | date =  | accessdate =  }}</ref>
 
==References==
 
{{Reflist|2}}
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]

Latest revision as of 21:12, 18 August 2015